- Home
- Pathology Industry
- All premium reports
- Phase Iii Clinical Trial Analysis & Statistics, May 2013
Talk to Robyn
00 1 718 213 49 04
Industries
- Pathology (149)
- Drug Discovery and Development (213)
- Drug and Medication (89)
- Therapy (47)
- Pharmaceutical (34)
-
- Biological Therapy (20)
- Medical Equipment and Supply (13)
- Biopharmaceutical (9)
- In Vitro Diagnostic (5)
- Healthcare (4)
- Juice (4)
- Biotechnology (3)
- Drug Delivery Technology (2)
- Electronic Component and Semiconductor (2)
- General Medicine and Specialty Medicine (2)
- Generic Drug (2)
- Genomics (2)
- Clean Vehicle (1)
- Diagnostics (1)
- Managed Care (1)
Top countries
Publication dates
Publishers
- Global Markets Direct (159)
- Global Data (146)
- Bioseeker (91)
- Global Industry Analyst (21)
- Datamonitor (20)
-
- GBI Research (11)
- BCC Research (6)
- MarketsandMarkets (3)
- Visiongain (3)
- CHI Insight Pharma Reports (2)
- Espicom Business Intelligence (2)
- Aruvian's R'search (1)
- Global Industry Analysts (1)
- Industry Experts (1)
- RNCOS (1)
- Timely Data Resources Inc. (1)
- Urch Publishing (1)
- Business Monitor International (119)
All regions
-
- Benin (1)
- Botswana (1)
- Burkina Faso (1)
- Cameroon (1)
- Congo, Democratic Republic Of (1)
- Egypt (1)
- Ethiopia (1)
- Gabon (1)
- Gambia (1)
- Ghana (1)
- Guinea (1)
- Guinea Bissau (1)
- Kenya (1)
- Madagascar (1)
- Malawi (1)
- Mali (1)
- Morocco (1)
- Mozambique (1)
- Nigeria (1)
- Rwanda (1)
- Senegal (1)
- South Africa (1)
- Sudan (1)
- Togo (1)
- Tunisia (1)
- Uganda (1)
- Zambia (1)
- Zimbabwe (1)
-
- Afghanistan (1)
- Armenia (1)
- Bangladesh (1)
- Cambodia (1)
- China (20)
- India (17)
- Indonesia (1)
- Iran (1)
- Israel (3)
- Japan (71)
- Jordan (1)
- Kazakhstan (1)
- Laos (1)
- Lebanon (1)
- Malaysia (1)
- Nepal (1)
- Oman (1)
- Pakistan (1)
- Philippines (1)
- Qatar (1)
- Saudi Arabia (1)
- Singapore (3)
- South Korea (5)
- Sri Lanka (1)
- Taiwan (2)
- Thailand (2)
- Turkey (1)
- United Arab Emirates (1)
- Vietnam (1)
-
- Albania (1)
- Austria (1)
- Belarus (1)
- Belgium (4)
- Cyprus (1)
- Czech Republic (1)
- Denmark (2)
- Finland (2)
- France (49)
- Germany (55)
- Greece (1)
- Hungary (1)
- Iceland (1)
- Ireland (1)
- Italy (48)
- Lithuania (1)
- Luxembourg (2)
- Macedonia (1)
- Malta (1)
- Netherlands (1)
- Norway (1)
- Poland (2)
- Portugal (1)
- Romania (1)
- Russian Federation (5)
- Slovakia (slovak Republic) (1)
- Slovenia (1)
- Spain (46)
- Sweden (8)
- Switzerland (5)
- Ukraine (2)
- United Kingdom (56)
-
- Australia (6)
- Austria (1)
- Belgium (4)
- Canada (17)
- Chile (1)
- Czech Republic (1)
- Denmark (2)
- Finland (2)
- France (49)
- Germany (55)
- Greece (1)
- Hungary (1)
- Iceland (1)
- Ireland (1)
- Israel (3)
- Italy (48)
- Japan (71)
- Luxembourg (2)
- Mexico (3)
- Netherlands (1)
- New Zealand (1)
- Norway (1)
- Poland (2)
- Portugal (1)
- Slovenia (1)
- South Korea (5)
- Spain (46)
- Sweden (8)
- Switzerland (5)
- Turkey (1)
- United Kingdom (56)
- United States (186)
data types
» Purchase Premium Reports
1-18 of about 600 reports for Phase Iii Clinical Trial
Orphan Drug Trends 2011
- $ 5 700
- Industry report
- November 2011
- by Datamonitor
... Or acquisition to rapidly access the target company's orphan drug portfolio, as illustrated by sanofi's purchase of genzyme.The majority of orphan drug cands targeted by pharma are in phase iii clinical ...
- Industries : Drug and Medication
- Countries : South Korea, Japan, Europe, United States, World, Australia, Singapore, Brazil, Mexico, Canada, United Kingdom, Sweden, Russian Federation, Germany, Taiwan, India, China, Asia
Australia Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2011
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : Australia
United Kingdom Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : United Kingdom
Singapore Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : Singapore
Canada Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : Canada
France Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : France
Brazil Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : Brazil
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
- $ 3 500
- Industry report
- January 2012
- by GBI Research
... Ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, most promising drugs with more emphasis on safety, efficacy and clinical trial details, and terminated trial ...
- Industries : Drug Discovery and Development
- Countries : World
United States Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : United States
South Korea Phase Iii Clinical Trials
- $ 250
- Industry data
- January 2013
Yearly, From 2006 To 2010
By Business Monitor International
Source: ClinicalTrials.gov, BMI. N.B. Sourced by date of initial registration.
- Industries : Drug Discovery and Development
- Countries : South Korea
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
- $ 3 500
- Industry report
- November 2011
- by GBI Research
... Phase ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, most promising central nervous system drugs with details on safety, efficacy and clinical trials ...
- Industries : Drug Discovery and Development
- Countries : World
Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
- $ 3 500
- Industry report
- January 2012
- by GBI Research
... Cardiovascular drugs, with an emphasis on safety and efficacy details, phase ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, the most promising cardiovascular drugs ...
- Industries : Drug Discovery and Development
- Countries : World
Endpoints - Clinical Trials in Autoimmune Disorders - Multiple Primary and Secondary Endpoints are Increasingly Being Applied to Ensure Success
- $ 3 500
- Industry report
- February 2012
- by GBI Research
... With an emphasis on safety and efficacy details, phase ii and phase iii clinical trial analysis for both completed and ongoing clinical trials, most promising autoimmune drugs, and terminated trial analysis ...
Orphan Drug Trends 2011
- $ 5 700
- Industry report
- November 2011
- by Datamonitor
... Or acquisition to rapidly access the target company's orphan drug portfolio, as illustrated by sanofi's purchase of genzyme.The majority of orphan drug cands targeted by pharma are in phase iii clinical ...
- Industries : Drug and Medication
- Countries : South Korea, Japan, Europe, United States, World, Australia, Singapore, Brazil, Mexico, Canada, United Kingdom, Sweden, Russian Federation, Germany, Taiwan, India, China, Asia
Biodel Inc. (BIOD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- $ 250
- Company report
- March 2012
- by Global Data
... Linjeta formerly known as viaject, has been studied in two pivotal phase iii clinical trials for the treatment of patients with type 1 and type 2 diabetes. The products in the pipeline are linjeta, viatab ...
- Industries : Drug Discovery and Development
- Countries : United States, Europe, World
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
- $ 3 500
- Industry report
- June 2012
- by GBI Research
... Distribution of clinical trials, by company (%), 2000-2010 79figure 21: endpoints - clinical trials in respiratory disorders, copd, global, primary endpoint analysis of completed phase iii clinical trials ...
- Industries : Drug Discovery and Development
- Countries : World
Xgeva's Safety and Efficacy Failings Put Future of Amgen Drug in Question
- $ 500
- Industry report
- February 2012
- by Global Data
... List of tablestable 1: selected phase iii clinical trials in castration-resistant prostate cancer patients 3list of figuresfigure 1: denosumab approval timelines 2 ...
- Industries : Pathology
- Countries : United States
Disease and Therapy Review: Parkinson%s Disease
- $ 995
- Industry report
- June 2012
- by Timely Data Resources Inc.
... Commentsselect therapies in post-market development or phase iii clinical trialsreferences/resources ...
» Download Public Reports
About 5 000 reports for Phase Iii Clinical Trial
Clinical Trial in India : Innovation and Technology Trends
- Industry report
- May 2011
- 9 pages
Clinical Trial Business In North America
September 2010» Read our Company Profiles
19 Companies for Phase Iii Clinical TrialGlaxoSmithKline P.L.C.
United StatesNovartis Inc.
SwitzerlandJohnson and Johnson
United StatesGlaxoSmithKline PLC
United KingdomPfizer Inc.
United StatesReportlinker.com © Copyright 2013. All rights reserved.
